Nifty
:
17781.90
Sensex
:
59979.62
119.75 (0.68%)
429.72 (0.72%)
Nifty
Sensex
:
:
17781.90
59979.62
119.75 (0.68%)
429.72 (0.72%)

Aurobindo Pharma Ltd.

Pharmaceuticals & Drugs - Global

Rating :
47/99

BSE: 524804 | NSE: AUROPHARMA

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 23,923.87
  • 11.33
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 22,106.63
  • 2.20%
  • 0.94

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.83%
  • 0.59%
  • 9.42%
  • FII
  • DII
  • Others
  • 22.31%
  • 14.65%
  • 1.20%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.89
  • 7.34
  • 0.51

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.68
  • 3.06
  • -2.06

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 24.74
  • 2.06
  • -2.15

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.19
  • 13.67
  • 12.30

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.67
  • 2.37
  • 2.04

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 11.11
  • 9.17
  • 8.35

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 22
Sep 21
Var%
Jun 22
Jun 21
Var%
Mar 22
Mar 21
Var%
Dec 21
Dec 20
Var%
Net Sales
5,739.37
5,941.92
-3.41%
6,235.92
5,701.98
9.36%
5,809.37
6,001.50
-3.20%
6,002.22
6,364.91
-5.70%
Expenses
4,948.58
4,755.20
4.07%
5,299.44
4,492.60
17.96%
4,834.97
4,726.83
2.29%
4,985.95
4,996.33
-0.21%
EBITDA
790.79
1,186.72
-33.36%
936.48
1,209.38
-22.57%
974.40
1,274.67
-23.56%
1,016.27
1,368.58
-25.74%
EBIDTM
13.78%
19.97%
15.02%
21.21%
16.77%
21.24%
16.93%
21.50%
Other Income
57.19
96.58
-40.78%
40.62
109.90
-63.04%
48.88
78.10
-37.41%
64.99
133.40
-51.28%
Interest
25.29
10.42
142.71%
14.63
12.88
13.59%
9.21
18.22
-49.45%
16.13
19.49
-17.24%
Depreciation
298.10
294.21
1.32%
279.51
279.69
-0.06%
253.57
266.00
-4.67%
299.05
276.52
8.15%
PBT
524.59
978.67
-46.40%
682.96
1,026.71
-33.48%
597.74
1,069.24
-44.10%
800.87
4,019.86
-80.08%
Tax
112.99
270.91
-58.29%
158.61
247.74
-35.98%
17.49
259.69
-93.27%
189.49
1,057.48
-82.08%
PAT
411.60
707.76
-41.84%
524.35
778.97
-32.69%
580.25
809.55
-28.32%
611.38
2,962.38
-79.36%
PATM
7.17%
11.91%
8.41%
13.66%
9.99%
13.49%
10.19%
46.54%
EPS
6.99
11.90
-41.26%
8.88
13.14
-32.42%
9.84
13.68
-28.07%
10.32
50.32
-79.49%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Net Sales
23,786.88
23,455.49
24,774.62
23,098.51
19,563.55
16,463.03
14,909.54
13,794.65
12,120.52
8,099.79
5,855.32
Net Sales Growth
-0.93%
-5.32%
7.26%
18.07%
18.83%
10.42%
8.08%
13.81%
49.64%
38.33%
 
Cost Of Goods Sold
10,723.17
9,238.91
8,827.71
8,720.74
7,886.32
6,085.55
5,911.00
5,612.30
5,099.89
3,275.54
2,730.00
Gross Profit
13,063.71
14,216.58
15,946.91
14,377.77
11,677.23
10,377.48
8,998.54
8,182.35
7,020.63
4,824.25
3,125.32
GP Margin
54.92%
60.61%
64.37%
62.25%
59.69%
63.04%
60.35%
59.32%
57.92%
59.56%
53.38%
Total Expenditure
20,068.94
19,070.95
19,441.22
18,234.20
15,611.61
12,691.28
11,475.26
10,606.53
9,556.90
5,966.14
4,994.37
Power & Fuel Cost
-
626.86
589.28
587.68
556.79
470.95
437.14
419.26
359.60
349.84
324.72
% Of Sales
-
2.67%
2.38%
2.54%
2.85%
2.86%
2.93%
3.04%
2.97%
4.32%
5.55%
Employee Cost
-
3,450.92
3,535.02
3,219.18
2,584.87
2,130.84
1,767.76
1,542.62
1,302.26
802.43
663.31
% Of Sales
-
14.71%
14.27%
13.94%
13.21%
12.94%
11.86%
11.18%
10.74%
9.91%
11.33%
Manufacturing Exp.
-
2,502.98
2,875.39
2,331.41
2,037.95
1,611.12
1,309.64
1,256.18
1,022.70
772.04
623.04
% Of Sales
-
10.67%
11.61%
10.09%
10.42%
9.79%
8.78%
9.11%
8.44%
9.53%
10.64%
General & Admin Exp.
-
1,335.03
1,473.59
1,320.69
1,006.68
1,068.22
997.32
686.38
666.38
283.49
197.83
% Of Sales
-
5.69%
5.95%
5.72%
5.15%
6.49%
6.69%
4.98%
5.50%
3.50%
3.38%
Selling & Distn. Exp.
-
1,496.67
1,564.17
1,524.75
1,125.76
1,025.85
848.43
877.14
878.98
359.60
305.98
% Of Sales
-
6.38%
6.31%
6.60%
5.75%
6.23%
5.69%
6.36%
7.25%
4.44%
5.23%
Miscellaneous Exp.
-
419.58
576.06
529.75
413.24
298.75
203.97
212.65
227.09
123.20
305.98
% Of Sales
-
1.79%
2.33%
2.29%
2.11%
1.81%
1.37%
1.54%
1.87%
1.52%
2.55%
EBITDA
3,717.94
4,384.54
5,333.40
4,864.31
3,951.94
3,771.75
3,434.28
3,188.12
2,563.62
2,133.65
860.95
EBITDA Margin
15.63%
18.69%
21.53%
21.06%
20.20%
22.91%
23.03%
23.11%
21.15%
26.34%
14.70%
Other Income
211.68
322.58
380.85
191.87
155.32
101.98
115.89
203.80
96.71
21.56
28.54
Interest
65.26
48.64
74.49
305.13
262.60
77.72
66.72
256.70
159.87
310.16
266.64
Depreciation
1,130.23
1,126.52
1,055.39
966.71
667.95
557.97
427.63
392.37
332.61
312.53
248.74
PBT
2,606.16
3,531.96
4,584.37
3,784.34
3,176.71
3,238.04
3,055.82
2,742.85
2,167.85
1,532.52
374.11
Tax
478.58
725.63
2,009.77
899.35
726.85
818.27
759.65
720.71
596.59
363.45
82.71
Tax Rate
18.36%
21.32%
27.16%
23.93%
23.53%
25.27%
24.86%
26.28%
27.52%
23.72%
22.11%
PAT
2,127.58
2,679.40
5,390.20
2,860.31
2,362.03
2,420.03
2,296.64
2,023.64
1,575.77
1,172.85
293.86
PAT before Minority Interest
2,127.58
2,678.36
5,389.18
2,858.86
2,361.80
2,419.77
2,296.17
2,022.14
1,571.26
1,169.07
291.40
Minority Interest
0.00
1.04
1.02
1.45
0.23
0.26
0.47
1.50
4.51
3.78
2.46
PAT Margin
8.94%
11.42%
21.76%
12.38%
12.07%
14.70%
15.40%
14.67%
13.00%
14.48%
5.02%
PAT Growth
-59.54%
-50.29%
88.45%
21.10%
-2.40%
5.37%
13.49%
28.42%
34.35%
299.12%
 
EPS
36.31
45.73
92.00
48.82
40.31
41.30
39.20
34.54
26.89
20.02
5.02

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Shareholder's Funds
24,575.98
21,929.87
16,824.67
13,890.78
11,680.42
9,371.91
7,287.30
5,155.91
3,750.15
2,605.76
Share Capital
58.59
58.59
58.59
58.59
58.59
58.59
58.52
29.20
29.15
29.12
Total Reserves
24,517.39
21,871.28
16,766.08
13,832.13
11,621.76
9,313.22
7,227.50
5,126.71
3,721.00
2,576.64
Non-Current Liabilities
903.10
807.27
555.09
358.13
594.11
102.07
583.85
1,591.60
1,493.91
1,225.26
Secured Loans
249.21
168.49
0.00
48.88
451.20
177.59
380.10
773.54
1,101.31
1,084.11
Unsecured Loans
0.00
0.00
0.00
131.07
0.00
3.81
362.71
587.93
178.05
64.15
Long Term Provisions
171.79
157.11
74.71
46.54
55.86
39.13
23.36
24.35
9.18
9.00
Current Liabilities
8,155.98
10,665.05
11,384.64
12,020.57
8,665.89
6,605.60
7,840.22
6,136.40
4,220.04
3,430.83
Trade Payables
2,703.05
2,794.68
2,576.06
2,552.18
2,372.90
2,154.70
2,457.03
2,051.13
1,351.20
963.75
Other Current Liabilities
3,106.51
2,684.31
2,874.56
2,510.51
1,967.42
1,286.82
1,577.58
1,364.95
387.68
150.87
Short Term Borrowings
2,117.83
4,803.78
5,422.30
6,573.21
4,031.34
2,902.72
3,672.68
2,502.08
2,354.56
2,236.12
Short Term Provisions
228.59
382.28
511.72
384.67
294.23
261.36
132.93
218.24
126.60
80.09
Total Liabilities
33,633.13
33,401.31
28,764.54
26,271.07
20,942.24
16,081.66
15,713.92
12,909.73
9,489.77
7,272.85
Net Block
10,532.09
9,373.58
9,396.47
8,474.85
6,520.68
4,833.78
4,179.69
3,705.64
2,721.67
2,638.87
Gross Block
15,943.09
13,613.33
12,441.26
10,497.62
7,894.78
5,635.49
4,569.83
5,446.13
4,182.96
3,763.47
Accumulated Depreciation
5,411.00
4,239.75
3,044.79
2,022.77
1,374.10
801.71
390.14
1,740.49
1,461.29
1,124.60
Non Current Assets
15,510.44
13,577.80
12,352.03
10,938.77
8,764.08
6,875.48
5,419.57
4,610.93
3,858.59
3,136.10
Capital Work in Progress
3,747.20
3,061.53
1,985.92
1,668.46
1,583.04
1,458.08
848.14
370.35
256.67
167.82
Non Current Investment
618.30
431.22
554.69
360.20
311.52
245.85
122.94
0.14
19.76
22.24
Long Term Loans & Adv.
575.33
658.44
378.34
396.64
261.91
256.48
236.56
455.27
789.04
237.82
Other Non Current Assets
37.52
53.03
36.61
38.62
86.93
81.29
32.24
30.25
18.40
18.66
Current Assets
18,122.69
19,823.51
16,412.51
15,332.30
12,178.16
9,206.18
10,294.35
8,298.80
5,631.18
4,136.75
Current Investments
378.85
159.79
0.02
0.02
0.02
0.02
0.02
19.65
0.03
0.04
Inventories
7,553.85
9,026.57
7,699.87
7,245.60
5,858.41
4,330.54
4,056.14
3,611.30
2,367.54
1,923.59
Sundry Debtors
4,012.26
3,503.28
4,315.16
3,413.78
3,080.20
2,765.33
4,606.68
3,539.17
2,636.57
1,596.98
Cash & Bank
4,190.01
5,474.28
2,842.15
1,957.18
1,262.25
513.48
800.26
469.11
178.58
208.45
Other Current Assets
1,987.72
601.29
489.35
1,919.82
1,977.28
1,596.81
831.25
659.57
448.46
407.69
Short Term Loans & Adv.
1,514.67
1,058.30
1,065.96
795.90
753.96
512.09
366.88
387.90
237.22
207.51
Net Current Assets
9,966.71
9,158.46
5,027.87
3,311.73
3,512.27
2,600.58
2,454.13
2,162.40
1,411.14
705.92
Total Assets
33,633.13
33,401.31
28,764.54
26,271.07
20,942.24
16,081.66
15,713.92
12,909.73
9,489.77
7,272.85

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Cash From Operating Activity
5,016.48
3,329.05
4,381.28
1,650.97
1,954.52
3,278.58
1,419.76
1,236.81
646.28
274.87
PBT
3,372.74
7,343.59
3,743.04
3,091.35
3,241.18
3,060.84
2,744.30
2,167.85
1,532.52
374.11
Adjustment
1,344.13
-1,662.64
1,091.17
813.95
535.02
408.92
487.50
406.28
515.12
441.54
Changes in Working Capital
1,557.80
-1,066.65
307.91
-1,484.50
-1,123.12
582.52
-1,079.41
-841.73
-1,057.41
-421.56
Cash after chg. in Working capital
6,274.67
4,614.30
5,142.12
2,420.80
2,653.08
4,052.28
2,152.39
1,732.40
990.23
394.09
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,258.19
-1,285.25
-760.84
-769.83
-698.56
-773.70
-732.63
-495.59
-343.95
-119.22
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-3,211.56
598.69
-1,567.64
-2,902.59
-1,926.59
-1,787.04
-1,445.21
-1,397.97
-818.74
-246.34
Net Fixed Assets
1,473.74
-428.03
-760.60
-799.00
-771.00
-1,092.24
125.11
-533.87
-141.02
-224.46
Net Investments
-1,574.43
-2,482.52
-188.35
-371.56
-285.55
-498.60
-170.60
-140.13
-164.64
-78.98
Others
-3,110.87
3,509.24
-618.69
-1,732.03
-870.04
-196.20
-1,399.72
-723.97
-513.08
57.10
Cash from Financing Activity
-2,969.27
-1,364.94
-1,947.18
1,919.06
864.15
-1,915.26
365.44
93.21
117.64
108.09
Net Cash Inflow / Outflow
-1,164.35
2,562.80
866.46
667.44
892.08
-423.72
339.99
-67.95
-54.82
136.62
Opening Cash & Equivalents
5,329.91
2,746.82
1,875.58
1,209.94
318.03
743.49
403.81
148.02
202.73
65.64
Closing Cash & Equivalent
4,162.51
5,329.91
2,746.82
1,875.58
1,209.94
319.63
743.50
461.10
148.02
202.73

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Book Value (Rs.)
419.46
374.29
287.16
237.08
199.36
159.96
124.50
88.29
64.33
44.74
ROA
7.99%
17.34%
10.39%
10.00%
13.07%
14.44%
14.13%
14.03%
13.95%
4.32%
ROE
11.52%
27.81%
18.62%
18.47%
22.99%
27.57%
32.51%
35.29%
36.79%
11.78%
ROCE
12.82%
30.33%
18.79%
17.97%
22.72%
24.92%
27.35%
27.18%
27.18%
11.17%
Fixed Asset Turnover
3.24
3.73
4.12
4.36
2.44
2.96
2.79
2.55
2.08
1.75
Receivable days
28.69
29.37
29.85
29.56
64.66
89.16
106.53
91.84
93.55
86.28
Inventory Days
63.29
62.82
57.72
59.64
112.70
101.43
100.27
88.91
94.82
105.51
Payable days
108.60
111.03
53.30
58.56
67.77
75.73
81.70
67.49
71.06
57.79
Cash Conversion Cycle
-16.62
-18.84
34.27
30.63
109.58
114.86
125.10
113.25
117.31
134.00
Total Debt/Equity
0.10
0.23
0.33
0.50
0.41
0.36
0.69
0.86
1.01
1.32
Interest Cover
70.98
100.33
13.32
12.76
42.66
46.80
11.69
14.56
5.94
2.40

Annual Reports:

FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013

News Update:


  • Aurobindo Pharma’s arm gets 2 observations from USFDA
    19th Jan 2023, 09:48 AM

    The observations are procedural in nature

    Read More
  • Aurobindo Pharma’s arm gets final approval from USFDA for Azacitidine Injection
    4th Jan 2023, 11:19 AM

    The product is expected to be launched by this month

    Read More
  • Aurobindo Pharma’s JV receives SEC recommendation for pneumococcal 15 valent vaccine
    27th Dec 2022, 14:15 PM

    Aurobindo Pharma holds 80% stake in the Joint Venture company, Tergene Biotech

    Read More
  • Aurobindo Pharma’s arm enters into license agreement with Evive Biotech
    23rd Nov 2022, 12:26 PM

    The Biologics License Application of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia

    Read More
  • Aurobindo Pharma aiming to complete Pen G plant in Andhra Pradesh by March 2024
    22nd Nov 2022, 15:30 PM

    The production capacity of the plant will be around 15,000 tonnes annually

    Read More
  • USFDA concludes inspection at Aurobindo Pharma’s Telangana facility
    19th Nov 2022, 12:45 PM

    At the end of the inspection, the Company has been issued a ‘Form 483’ with 10 observations

    Read More
  • Aurobindo Pharma’s arm receives USFDA approval for Amphotericin B Liposome for Injection.
    18th Nov 2022, 10:58 AM

    The approved product has an estimated market size of around $145 million

    Read More
  • Aurobindo Pharma gets EIR from USFDA for manufacturing facility in Andhra Pradesh
    17th Nov 2022, 10:37 AM

    The company's Unit XI at Pydibhimavaram is an API non-antibiotic manufacturing facility

    Read More
  • Aurobindo Pharma reports 41% fall in Q2 consolidated net profit
    14th Nov 2022, 11:59 AM

    Total consolidated income of the company decreased by 4.01% at Rs 5796.56 crore for Q2FY23

    Read More
  • Aurobindo Pharma - Quarterly Results
    12th Nov 2022, 17:31 PM

    Read More
  • Aurobindo Pharma’s unit recalling 88,080 vials of Tranexamic acid injection
    25th Oct 2022, 10:27 AM

    AuroMedics commenced the Class III recall in the US on September 26

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.